Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product can ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _______________________________________________________________________________________________________________________________ FORM 10-K _______________________________________________________________________________________________________________________________ ________________________________________________________________________________________________________________ Tempest Therapeutics, Inc. (Exact Name of Registrant as Specifi ...

Exhibit 99.1 Tempest Reports Year End 2025 Financial Results and Provides Business Update Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Brisbane, CA, March 30, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest"), a clinical- stage biotechnology com ...

$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrantsBRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or ...

Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026Selection of tech transfer partner follows Tempest’s recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% CR in all six efficacy evaluable patients, and accelerated development timel ...

Core Insights - Tempest Therapeutics announced promising clinical data from the ongoing REDEEM-1 Phase 1/2a trial for TPST-2003, a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma [1][6] Clinical Data Summary - TPST-2003 is designed to enhance response depth and durability in patients with relapsed/refractory multiple myeloma through a dual-targeting CAR structure [2] - As of January 31, 2026, 36 patients with relapsed/refractory multiple myeloma have received TPST-2003, with a median of four prior lines of therapy [3] - All six evaluable patients in the REDEEM-1 trial achieved a complete response (CR), resulting in an overall response rate (ORR) of 100% among 25 evaluable patients [4][8] Safety Profile - TPST-2003 demonstrated a favorable safety profile across all dose levels, with no Grade >3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported [7][9] - The prior investigator-initiated trial (IIT) showed a median progression-free survival (PFS) of 23.1 months, including patients with extramedullary disease [8][10] Future Development Plans - Tempest plans to accelerate the development of TPST-2003 and intends to submit a U.S. IND application, aiming to initiate a U.S. registrational study in 2026 [6][15] - The company is also exploring the potential of TPST-2003 for treating large B-cell lymphoma and other related indications [6][12] Treatment Landscape - Approved CAR-T therapies have shown clinical benefits in relapsed/refractory multiple myeloma, but challenges such as relapse and toxicity management remain prevalent [13] - TPST-2003's dual-targeting CAR structure aims to address tumor heterogeneity and antigen escape, which are significant factors in disease progression [14]

Core Insights - Tempest Therapeutics, Inc. is advancing its CAR-T assets post-transaction while maintaining a capital-efficient operational model [1][6] Strategic Priorities - The company will prioritize the development of its dual-targeting CD19/BCMA CAR-T program, TPST-2003, with clinical data expected from an ongoing Phase 1 trial in China and a registrational Phase 2b trial anticipated to start by the end of 2026 [2][3] - TPST-4003, an in vivo CAR-T program, aims to deliver the same dual-targeting construct without ex vivo cell manufacturing, with plans for preclinical development and potential clinical entry through a partner-funded trial [4][6] - Amezalpat is positioned for pivotal development in first-line hepatocellular carcinoma (HCC), with plans for business development discussions to advance this program [4] - The company plans to initiate a Phase 2 study of TPST-1495 in familial adenomatous polyposis (FAP), with first patient enrollment expected in Q1 2026, funded by the National Cancer Institute [5][6] Pipeline Expansion - Tempest is expanding its next-generation CAR-T pipeline, which includes additional dual-targeting CAR-T programs such as TPST-3003, TPST-2206, and TPST-3206 [6][7]

Core Insights - Tempest Therapeutics, Inc. has successfully closed an all-stock transaction to acquire dual-targeting CAR-T programs and secured financing support from Factor Bioscience Inc., enhancing its portfolio and operational runway [1][4] Group 1: Transaction Details - The transaction includes a diverse portfolio of clinical-stage product candidates and extends the operational runway to mid-2027, supporting multiple potential value-generating milestones [1][4] - The acquisition brings next-generation CAR-T assets, including TPST-2003, a dual-targeting CD-19/BCMA CAR-T, with a biologics license application (BLA) filing in China planned for 2027 [4][5] - The transaction was finalized following stockholder approval of share issuance at the 2025 Annual Meeting on January 27, 2026 [4] Group 2: Leadership Changes - Dr. Matt Angel has joined Tempest as President and CEO, expressing excitement about developing the innovative pipeline for treating solid tumors and hematologic malignancies [2][4] - Stephen Brady, Chair of the Board, acknowledged the contributions of outgoing board members and emphasized the importance of the transaction for the company's financial stability and future milestones [2][3] Group 3: Pipeline Developments - Amezalpat (TPST-1120) is ready for Phase 3 trials in first-line liver cancer, supported by global regulatory agreement and positive Phase 2 data [5] - TPST-2003 has completed Phase 1 trials in patients with relapsed/refractory multiple myeloma, with data expected in 2026 and a BLA in China planned for 2027 [5] - Tempest plans to initiate a Phase 2 study of TPST-1495 in familial adenomatous polyposis (FAP) in Q1 2026, funded by the National Cancer Institute [5][11]

BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the “Record Date”) for the distribution of warrants to purchase Tempest common stock (“Warrants”) as a dividend (the “Warrant Dividends”), as contemplated by Tempest’s previously announced Asset Purchase Agreement (the “Asset Purchase ...

Table of Contents FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TEMPEST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 45-1472564 (Primary Standard Industrial Code Number) As filed with the Securities and Exchange Commission on December 9, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (I.R.S. Employer Identification Number) 2000 Sierr ...